What is Genome?
Genome & Company operates at the intersection of microbiome research and novel target immune checkpoint inhibitors. As a publicly traded entity on the Korea Exchange (KRX: 314130), the organization is dedicated to the discovery and development of next-generation therapeutics. By leveraging diverse modalities, including fusion proteins and microbiome-based interventions, Genome is positioning itself as a leader in the competitive landscape of oncology drug development. The company's focus remains on translating complex biological insights into clinical-stage assets that offer meaningful improvements for patients facing unmet medical needs.
How much funding has Genome raised?
Genome has raised a total of $29.5M across 2 funding rounds:
Series A
$3M
Series B
$26.5M
Series A (2020): $3M with participation from DongKoo Bio& Pharma
Series B (2020): $26.5M led by Genome & Company
Key Investors in Genome
DongKoo Bio& Pharma
A South Korean pharmaceutical company with a strong focus on dermatology and innovative drug development, often acting as a strategic partner in the biotech ecosystem.
Genome & Company
The parent or internal entity providing capital to support the ongoing clinical research and development initiatives of its therapeutic pipeline.
What's next for Genome?
With the recent infusion of capital, Genome is well-positioned to accelerate its clinical development programs and expand its research capabilities. The strategic roadmap likely involves advancing its lead candidates through rigorous human trials while simultaneously refining its proprietary platform for immune checkpoint modulation. As the company transitions into a more mature phase of its lifecycle, the focus will shift toward data readout milestones and potential collaborative partnerships that could validate its therapeutic modalities on a global scale. Sustained investment will be pivotal in maintaining the momentum required to navigate the high-barrier entry of the international biotechnology market.
See full Genome company page
